NEVANAC

Novartis Pharmaceuticals Corporation🇺🇸 United States

FDA Page

Effective Date: Apr 19, 2023
Approval ID: a2909252-c5f1-421f-9073-b7be90b45b51
Products: 1 registered
Version: 2

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use NEVANAC safely and effectively. See full prescribing information for NEVANAC. NEVANAC (nepafenac ophthalmic suspension) 0.1%, for topical ophthalmic use Initial U.S. Approval: 2005

Quick Stats

Total Products1

Labelers2

Label Sections14

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.